Trispecific constructs targeting PSMA, CD3, and an albumin-binding domain have already entered clinical trials for PCa (e.g., HPN424) [12], illustrating how multispecificity can simultaneously boost half-life and tumor specificity. Here, FOLH1 is linked to neoplasm.